The common technical document: the changing face of the New Drug Application
Related Experiment Video
Updated: Sep 27, 2026

Chimeric Antigen Receptor T Cell Manufacturing on an Automated Cell Processor
Published on: August 18, 2023
1International Programs of the Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Lane, Rockville, Maryland 20857, USA. molzonj@cder.fda.gov
Abstract:
Drug approval is the goal of the long process of drug development. Once preclinical and clinical trial data have been collected, a New Drug Application must be submitted to the regulatory authority for approval. Although the requirements for this submission have similarities around the world, until now, the applications have been different. Regulatory authorities working under the umbrella of the International Conference on Harmonisation are hoping that the development of the Common Technical Document will soon harmonize the application procedure, and make this process simpler for applicants.
Related Concept Videos
FDA Approved Drugs: Changes to Approved Drugs
Clinically Relevant Drug Product Specifications: Methods of Establishment
Drug Nomenclature
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Modified-Release Drug Delivery Systems: Overview
Preclinical Development: Overview
